Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diclofenac + tolperisone
- Development stage
- Unknown
- Lead developer
- Sanrey Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tolipain is a fixed-dose combination of the non-steroidal anti-inflammatory drug (NSAID) diclofenac and the centrally acting muscle relaxant tolperisone. Developed by Sanrey Therapeutics, it is indicated for the treatment of pain, stiffness, and inflammation associated with musculoskeletal conditions and muscle spasms. Diclofenac acts by inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of inflammatory prostaglandins. Tolperisone acts as a muscle relaxant by blocking voltage-gated sodium and calcium channels, which inhibits synaptic transmission in the spinal cord and reduces muscle spasticity. This dual-action formulation provides synergistic relief from pain and muscle spasms, improving mobility and recovery in orthopedic and musculoskeletal disorders.
- Brand names
- TolipainTolipain D
- Other names
- diclofenac sodium + tolperisonetolperisone + diclofenac
02
Targets
P2X3 (P2X purinoceptor 3)CaV (Voltage-gated calcium channel protein complex)NaV (Voltage-gated sodium channels)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on diclofenac + tolperisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diclofenac + tolperisone.